Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells

Nature Reviews Immunology

Volumn 10, Issue 5, 2010, Pages 365-376

  Glass, Christopher K ^a   Saijo, Kaoru ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTROGEN RECEPTOR; FARNESOID X RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4; LIVER X RECEPTOR; MINERALOCORTICOID RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; REV PROTEIN; ROSIGLITAZONE; STEROIDOGENIC FACTOR 1; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; ENZYME REPRESSION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSOR; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; TRANSCRIPTION INITIATION; TURNOVER TIME;

ANIMALS; HUMANS; INFLAMMATION; MACROPHAGES; NUCLEAR RECEPTOR CO-REPRESSOR 1; NUCLEAR RECEPTOR CO-REPRESSOR 2; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; REPRESSOR PROTEINS; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION;

EID: 77951602823     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2748     Document Type: Review

References (80)

1. Chawla, A., Repa, J., Evans, R. & Mangelsdorf, D. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001). (Pubitemid 33101573)
2. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
3. Hench, P., Kendall, E., Slocumb, C. & Polley, H. The effect of a hormone of the adrenal cortex (17-hydroxyl-11-dehydrocortisone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181-197 (1948).
4. Glass, C. K. & Ogawa, S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nature Rev. Immunol. 6, 44-55 (2006).
5. Chinenov, Y. & Rogatsky, I. Glucocorticoids and the innate immune system: crosstalk with the Toll-like receptor signaling network. Mol. Cell. Endocrinol. 275, 30-42 (2007).
6. Zhou, L. & Littman, D. R. Transcriptional regulatory networks in Th17 cell differentiation. Curr. Opin. Immunol. 21, 146-152 (2009).
7. Medzhitov, R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1, 135-145 (2001).
8. Takeda, K. & Akira, S. Toll-like receptors. Curr. Protoc. Immunol. 14, 12 (2007).
9. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nature Rev. Immunol. 6, 823-835 (2006).
10. Miller, Y. I. et al. Toll-like receptor 4-dependent and-independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler. Thromb. Vasc. Biol. 25, 1213-1219 (2005).
11. Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 11 6, 3015-3025 (2006).
12. Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292 (2007).
13. Walter, S. et al. Role of the Toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol. Biochem. 20, 947-956 (2007).
14. Kim, F. et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100, 1589-1596 (2007).
15. Michelsen, K. S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004).
16. Mullick, A. E., Tobias, P. S. & Curtiss, L. K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 11 5, 3149-3156 (2005).
17. Poggi, M. et al. C3H/HeJ mice carrying a Toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50, 1267-1276 (2007).
18. Saberi, M. et al. Hematopoietic cell-specific deletion of Toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 10, 419-429 (2009).
19. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature Rev. Immunol. 4, 499-511 (2004).
20. Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
21. Werner, S. L., Barken, D. & Hoffmann, A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309, 1857-1861 (2005).
22. Aarnisalo, P., Kim, C. H., Lee, J. W. & Perlmann, T. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1. J. Biol. Chem. 277, 35118-35123 (2002).
23. Maira, M., Martens, C., Philips, A. & Drouin, J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol. Cell. Biol. 19, 7549-7557 (1999).
24. Wang, Z. et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423, 555-560 (2003).
25. Rosenfeld, M. G., Lunyak, V. V. & Glass, C. K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20, 1405-1428 (2006).
26. O'Malley, B. W., Qin, J. & Lanz, R. B. Cracking the coregulator codes. Curr. Opin. Cell Biol. 20, 310-315 (2008).
27. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213-219 (2003).
28. Odegaard, J. I. et al. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496-507 (2008).
29. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008).
30. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43 (2005).
31. Lefterova, M. I. et al. PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22, 2941-2952 (2008).
32. Nielsen, R. et al. Genome-wide profiling of PPARγ:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 22, 2953-2967 (2008).
33. + T helper cells. Cell 126, 1121-1133 (2006).
34. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
35. Barish, G. D. et al. A nuclear receptor atlas: macrophage activation. Mol. Endocrinol. 19, 2466-2477 (2005).
36. Bookout, A. L. et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789-799 (2006).
37. Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122, 707-721 (2005).
38. De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24, 488-522 (2003).
39. Quante, T. et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am. J. Respir. Cell Mol. Biol. 39, 208-217 (2008).
40. Beck, I. M. et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-κB inhibition. EMBO J. 27, 1682-1693 (2008).
41. Cho, I. J. & Kim, S. G. A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR. Mol. Endocrinol. 23, 86-99 (2009).
42. Diefenbacher, M. et al. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol. Endocrinol. 22, 1767-1780 (2008).
43. De Bosscher, K. & Haegeman, G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol. 23, 281-291 (2009).
44. Leung, T. H., Hoffmann, A. & Baltimore, D. One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 11 8, 453-464 (2004).
45. Luecke, H. F. & Yamamoto, K. R. The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev. 19, 1116-1127 (2005).
46. Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129-145 (2009).
47. Rogatsky, I., Luecke, H. F., Leitman, D. C. & Yamamoto, K. R. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc. Natl Acad. Sci. USA 99, 16701-16706 (2002).
48. Rogatsky, I., Zarember, K. A. & Yamamoto, K. R. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20, 6071-6083 (2001).
49. Kassel, O. et al. A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1-and NF-κB-regulated promoters. Genes Dev. 18, 2518-2528 (2004).
50. Ogawa, S. et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc. Natl Acad. Sci. USA 101, 14461-14466 (2004).
51. Pascual, G. et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-y. Nature 437, 759-763 (2005).
52. Chen, J. D. & Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454-457 (1995).
53. Horlein, A. J. et al. L igand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397-404 (1995).
54. Jepsen, K. & Rosenfeld, M. G. Biological roles and mechanistic actions of co-repressor complexes. J. Cell Sci. 115, 689-698 (2002).
55. Ghisletti, S. et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 23, 681-693 (2009).
56. Perissi, V., Aggarwal, A., Glass, C. K., Rose, D. W. & Rosenfeld, M. G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116, 511-526 (2004).
57. Frasor, J., Danes, J. M., Funk, C. C. & Katzenellenbogen, B. S. Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc. Natl Acad. Sci. USA 102, 13153-13157 (2005).
58. Ghisletti, S. et al. Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARy. Mol. Cell 25, 57-70 (2007).
59. Blaschke, F et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 99, e88-e99 (2006).
60. Venteclef, N. et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRß in the hepatic acute phase response. Genes Dev. 24, 381-395 (2010).
61. Huang, W., Ghisletti, S., Perissi, V., Rosenfeld, M. G. & Glass, C. K. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR depresssion checkpoint. Mol. Cell 10, 48-57 (2009).
62. Hong, S. H. & Privalsky, M. L. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol. Cell. Biol. 20, 6612-6625 (2000).
63. Jonas, B. A. & Privalsky, M. L. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J. Biol. Chem. 279, 54676-54686 (2004).
64. Roy, S. K. et al. MEKK1 plays a critical role in activating the transcription factor C/EBP-ß-dependent gene expression in response to IFN-y. Proc. Natl Acad. Sci. USA 99, 7945-7950 (2002).
65. Jepsen, K. et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450, 415-419 (2007).
66. Lee, J. H. et al. Differential SUMOylation of LXRα and LXRß mediates transrepression of STAT1 inflammatory signaling in IFN-y-stimulated brain astrocytes. Mol. Cell 35, 806-817 (2009).
67. Saijo, K. et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47-59 (2009).
68. Buss, H. et al. Phosphorylation of serine 468 by GSK-3ß negatively regulates basal p65 NF-?B activity. J. Biol. Chem. 279, 49571-49574 (2004).
69. Ashwell, J. D., Lu, F W. & Vacchio, M. S. Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 18, 309-345 (2000).
70. Yang, X. O. et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORy. Immunity 28, 29-39 (2008).
71. Korn, T. Pathophysiology of multiple sclerosis. J. Neurol. 255, S2-S6 (2008).
72. H 17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
73. Klotz, L. et al. The nuclear receptor PPARy selectively inhibits Th 17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206, 2079-2089 (2009).
74. Doi, Y. et al. Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc. Natl Acad. Sci. USA 105, 8381-8386 (2008).
75. Hermann-Kleiter, N. et al. The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity. Immunity 29, 205-216 (2008).
76. Luhder, F & Reichardt, H. M. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 29, 255-273 (2009).
77. Wust, S. et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 180, 8434-8443 (2008).
78. A-Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258 (2009).
79. Mukundan, L. et al. PPAR- senses and orchestrates clearance of apoptotic cells to promote tolerance. Nature Med. 15, 1266-1272 (2009).
80. Majai, G., Sarang, Z., Csomos, K., Zahuczky, G. & Fesus, L. PPARy-dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur. J. Immunol. 37, 1343-1354 (2007).